PVX 108
Alternative Names: Peanut allergy vaccine - Aravax; PVX-108Latest Information Update: 22 Nov 2024
At a glance
- Originator Aravax
- Class Peptides; Vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Peanut hypersensitivity
Most Recent Events
- 14 Nov 2024 Aravax plans a phase III trial for Peanut hypersensitivity
- 28 Oct 2024 Aravax completes enrolment in its phase II trial in Peanut hypersensitivity (In children, In adolescents) in Australia (Intradermal) (NCT05621317)
- 09 Feb 2023 Phase-II clinical trials in Peanut hypersensitivity (In children, In adolescents) in USA (Intradermal) (NCT05621317)